Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TACR2 | P21452 | 20/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Maleic Acid SCHEMBL6057634 | 1.00 | TACR2 (0.67) | TACR2 | |
| SCHEMBL29395251 | 0.96 | TACR2 (0.72) | TACR2 | |
| SCHEMBL1387902 | 0.96 | TACR2 (0.72) | TACR2 | |
| SCHEMBL1387904 | 0.96 | TACR2 (0.72) | TACR2 | |
| Hydrochloric Acid SCHEMBL5813499 | 0.95 | TACR2 (0.71) | TACR2 | |
| Hydrochloric Acid SCHEMBL6057713 | 0.95 | TACR2 (0.71) | TACR2 | |
| SCHEMBL9217768 | 0.94 | TACR2 (0.71) | TACR2 | |
| Hydrochloric Acid SCHEMBL7045673 | 0.93 | TACR2 (0.70) | TACR2 | |
| SCHEMBL8437859 | 0.92 | TACR2 (0.74) | TACR2 | |
| SCHEMBL7047293 | 0.92 | TACR2 (0.74) | TACR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1307202-B1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2006-05-17 | — | — | EP | disclosed |
| US-20030139433-A1 | Method for the treatment of overactive bladder | ASTRAZENECA AB (SE) | 2003-07-24 | — | — | US | disclosed |
| EP-1307202-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | AstraZeneca AB (SE) | 2003-05-07 | — | — | EP | disclosed |
| WO-2001097811-A1 | METHOD FOR THE TREATMENT OF OVERACTIVE BLADDER | ASTRAZENECA AB (SE) | 2001-12-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139433-A1 | Method for the treatment of overactive bladder | QDPR, PDE3A, HNMT | TACR2 75/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.